Panitumumab: new drug. Metastatic colorectal cancer: don't make things worse!
出版信息
Prescrire Int. 2009 Aug;18(102):157.
PMID:19743571
Abstract
摘要
相似文献
1
Panitumumab: new drug. Metastatic colorectal cancer: don't make things worse!
Prescrire Int. 2009 Aug;18(102):157.
2
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Cancer. 2007 Sep 1;110(5):980-8. doi: 10.1002/cncr.22915.
3
Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Ann Pharmacother. 2007 Apr;41(4):606-13. doi: 10.1345/aph.1H492. Epub 2007 Mar 13.
4
[Panitumumab].
Med Monatsschr Pharm. 2008 Apr;31(4):122-6.
5
[Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].
Gan To Kagaku Ryoho. 2010 May;37(5):787-90.
6
Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Pharmacotherapy. 2008 Nov;28(11 Pt 2):31S-41S. doi: 10.1592/phco.28.11-supp.31S.
7
Panitumumab in the treatment of metastatic colorectal cancer: profile report.
BioDrugs. 2007;21(2):135-7. doi: 10.2165/00063030-200721020-00011.
8
Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Cancer Chemother Pharmacol. 2009 Dec;65(1):107-12. doi: 10.1007/s00280-009-1009-6. Epub 2009 May 5.
9
Panitumumab.
Nat Rev Drug Discov. 2006 Dec;5(12):987-8. doi: 10.1038/nrd2204.
10
Danitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer.
Prescrire Int. 2013 May;22(138):120.
Zotero 插件